Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) SVP James B. Jones sold 850 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $41.11, for a total transaction of $34,943.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pacira Pharmaceuticals, Inc. (PCRX) opened at $42.20 on Tuesday. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same period last year, the company posted $0.20 earnings per share. Pacira Pharmaceuticals’s quarterly revenue was down 1.6% on a year-over-year basis. research analysts expect that Pacira Pharmaceuticals, Inc. will post -0.87 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) SVP James B. Jones Sells 850 Shares of Stock” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/21/pacira-pharmaceuticals-inc-pcrx-svp-james-b-jones-sells-850-shares-of-stock.html.

A number of equities research analysts have weighed in on PCRX shares. Mizuho restated a “buy” rating and issued a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Canaccord Genuity set a $56.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, July 25th. BidaskClub cut shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Royal Bank Of Canada set a $58.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, July 30th. Finally, Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $49.71.

Institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its holdings in shares of Pacira Pharmaceuticals by 9.1% in the 2nd quarter. Northern Trust Corp now owns 505,529 shares of the company’s stock worth $24,114,000 after acquiring an additional 42,289 shares during the last quarter. State Street Corp lifted its holdings in shares of Pacira Pharmaceuticals by 1.0% in the 2nd quarter. State Street Corp now owns 1,118,083 shares of the company’s stock worth $53,340,000 after acquiring an additional 10,727 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Pacira Pharmaceuticals by 40.9% in the 2nd quarter. Baillie Gifford & Co. now owns 301,000 shares of the company’s stock worth $14,358,000 after acquiring an additional 87,400 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in shares of Pacira Pharmaceuticals by 40.4% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 191,224 shares of the company’s stock worth $9,121,000 after acquiring an additional 55,057 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its holdings in shares of Pacira Pharmaceuticals by 5.1% in the 2nd quarter. Stephens Investment Management Group LLC now owns 942,969 shares of the company’s stock worth $44,980,000 after acquiring an additional 45,514 shares during the last quarter. Hedge funds and other institutional investors own 99.79% of the company’s stock.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.